Chelariu-Raicu A[Author] - Search Results

Year	Number of Results
2016	1
2019	1
2020	9
2021	4

1

Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer.

Slomovitz BM, Chelariu-Raicu A, Schmeler KM, Lu KH, Gershenson DM, Wolf J, Coleman RL. Slomovitz BM, et al. Among authors: chelariu raicu a. Int J Gynecol Cancer. 2020 Nov;30(11):1733-1737. doi: 10.1136/ijgc-2020-001859. Epub 2020 Oct 5. Int J Gynecol Cancer. 2020. PMID: 33020204

2

Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?

Chelariu-Raicu A, Coleman RL, Sood AK. Chelariu-Raicu A, et al. Oncology (Williston Park). 2019 Jul 16;33(7):629378. Oncology (Williston Park). 2019. PMID: 31365748 Free article. Review.

3

The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers.

Chelariu-Raicu A, Zibetti Dal Molin G, Coleman RL. Chelariu-Raicu A, et al. Int J Gynecol Cancer. 2020 Oct;30(10):1608-1618. doi: 10.1136/ijgc-2020-001789. Epub 2020 Sep 14. Int J Gynecol Cancer. 2020. PMID: 32928926 Review.

4

Breast cancer (BRCA) gene testing in ovarian cancer.

Chelariu-Raicu A, Coleman RL. Chelariu-Raicu A, et al. Chin Clin Oncol. 2020 Oct;9(5):63. doi: 10.21037/cco-20-4. Epub 2020 Aug 19. Chin Clin Oncol. 2020. PMID: 32819112 Free article.

5

Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancer.

Kim MS, Ma S, Chelariu-Raicu A, Leuschner C, Alila HW, Lee S, Coleman RL, Sood AK. Kim MS, et al. Among authors: chelariu raicu a. Mol Cancer Ther. 2020 Sep 17:molcanther.0030.2020. doi: 10.1158/1535-7163.MCT-20-0030. Online ahead of print. Mol Cancer Ther. 2020. PMID: 32943548

6

Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile.

Zheng M, Mullikin H, Hester A, Czogalla B, Heidegger H, Vilsmaier T, Vattai A, Chelariu-Raicu A, Jeschke U, Trillsch F, Mahner S, Kaltofen T. Zheng M, et al. Among authors: chelariu raicu a. Int J Mol Sci. 2020 Dec 1;21(23):9169. doi: 10.3390/ijms21239169. Int J Mol Sci. 2020. PMID: 33271935 Free PMC article.

7

Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.

Xiong C, Wen Y, Zhao J, Yin D, Xu L, Chelariu-Raicu A, Yao C, Leng X, Liu J, Chaudhari RR, Zhang S, Sood AK, Li C. Xiong C, et al. Among authors: chelariu raicu a. Sci Rep. 2020 Jan 16;10(1):520. doi: 10.1038/s41598-020-57477-x. Sci Rep. 2020. PMID: 31949258 Free PMC article.

8

Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer.

Chelariu-Raicu A, Levenback CF, Slomovitz BM, Wolf J, Bodurka DC, Kavanagh JJ, Morrison C, Gershenson DM, Coleman RL. Chelariu-Raicu A, et al. Int J Gynecol Cancer. 2020 Nov;30(11):1768-1774. doi: 10.1136/ijgc-2020-001863. Epub 2020 Oct 9. Int J Gynecol Cancer. 2020. PMID: 33037105

9

Fertility preservation in rare ovarian tumors.

Chelariu-Raicu A, Cobb LP, Gershenson DM. Chelariu-Raicu A, et al. Int J Gynecol Cancer. 2021 Mar;31(3):432-441. doi: 10.1136/ijgc-2020-001775. Int J Gynecol Cancer. 2021. PMID: 33649010 Review.

10

A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.

Chelariu-Raicu A, Nick A, Urban R, Gordinier M, Leuschner C, Bavisotto L, Molin GZD, Whisnant JK, Coleman RL. Chelariu-Raicu A, et al. Gynecol Oncol. 2021 Feb;160(2):418-426. doi: 10.1016/j.ygyno.2020.11.013. Epub 2020 Nov 23. Gynecol Oncol. 2021. PMID: 33243443

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results